Le. Visser et al., COUGH DUE TO ACE-INHIBITORS - A CASE-CONTROL STUDY USING AUTOMATED GENERAL-PRACTICE DATA, European Journal of Clinical Pharmacology, 49(6), 1996, pp. 439-444
Objectives: To determine the risk of coughing as an adverse reaction t
o ACE inhibitors under everyday circumstances in a large population, a
nd to study whether this adverse effect was duration or dose dependent
. Design: A population-based case-control study. Setting: Ten general
practices of 14 Dutch general practitioners (GP), in which all consult
ations, morbidity and medical interventions, including drugs prescribe
d, were registered over the 18 month period from 1st September, 1992 t
o 1st March, 1994. Subjects: 1458 patients with incident coughing and
up to four controls per case were obtained (total 4182 controls), matc
hed for GP. All cases and controls were 20 years or older and had no r
ecord of respiratory infection, influenza, tuberculosis, asthma, chron
ic bronchitis, emphysema, congestive heart failure, sinusitis, laryngi
tis, haemoptysis or respiratory neoplasms during the study period. Res
ults: Cases were 2.1-times more likely than controls to have been expo
sed to ACE inhibitors (95% CI 1.5-3.1), but after adjustment the odds
ratio was 1.4 (95% CI 0.9-2.1). The crude odds ratio for captopril was
1.3 (95% CI 0.7-2.5), for enalapril 2.6 (95% CI 1.6-4.2) and for lisi
nopril 2.0 (95% CI 0.5-9.3). The adjusted odds ratio for captopril was
0.9 (95% CI 0.4-1.7), for enalapril 1.7 (95% CI 1.03-2.8) and for lis
inopril 1.7 (95% CI 0.4-7.9). For patients who had been on ACE inhibit
or treatment for no longer than 2 months the odds ratio was 4.8 (95% C
I 1.7-13.3). The odds ratio declined to 2.0 (95% CI 1.1-3.8) for those
who had taken an ACE inhibitor for 2-6 months, and to 1.6 (95% CI 0.9
-2.7) for those on ACE-inhibitors for more than 6 months. Conclusion:
The risk of coughing was increased twofold among ACE inhibitor users,
but the odds ratios were no longer significant after controlling for s
everal confounding factors. The risk of developing cough due to ACE-in
hibitors declines with the duration of treatment, possibly due to depl
etion of susceptible persons.